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Abstract
Influenza has been circulating in the human population and has caused three pandemics in the last
century (1918 H1N1, 1957 H2N2, 1968 H3N2). The 2009 A(H1N1) was classified by the World Health
Organization (WHO) as the fourth pandemic. Influenza has a high evolution rate, which makes vaccine
design challenging. We here consider an approach for early detection of new dominant strains. By
clustering the 2009 A(H1N1) sequence data, we found two main clusters. We then define a metric to
detect the emergence of dominant strains. We show on historical H3N2 data that this method is able
to identify a cluster around an incipient dominant strain before it becomes dominant. For example, for
H3N2 as of March 30, 2009, the method detects the cluster for the new A/British Columbia/RV1222/2009
strain. This strain detection tool would appear to be useful for annual influenza vaccine selection.
Keywords: clustering/H1N1/H3N2/influenza
Introduction
The recent outbreak of 2009 A(H1N1) caused immediate international attention [1–4]. This new 2009
A(H1N1) virus contains a combination of gene segments from swine and human influenza viruses [2, 3].
Confirmed infections reached 270,000 globally as of September 2009 [5]. The novel 2009 A(H1N1) strain
was defined as a pandemic strain by the World health Organization(WHO) in 2009 [6], and was the
epidemic strain in the 2009 Northern winter.
Influenza viruses are hyper-mutating viruses. It has been estimated that the nucleotide mutation
rate per genome per replication is approximately 0.76 [7]. Influenza viruses escape the human immune
system by continual antigenic drift and shift [8–13]. The quasispecies nature of influenza viruses makes
the strain structure complex [14]. Usually, there is one or a few dominant influenza strains circulating
in the population for each flu season. The flu vaccine is most effective when it matches this dominant
circulating strain [15,16]. The degree to which immunity induced by a vaccine protects against a different
viral strain is determined by the antigenic distance between the vaccine and the virus. Due to evolution
of the antigenic regions of the influenza virus, the composition of the flu vaccine is typically modified
annually [17]. However, since the influenza strains used in the flu vaccine are decided 6 months before
the flu season, a mismatch between the vaccine strain and dominant circulating strain may occur if the
virus evolves significantly. Such a situation arose for the H3N2 virus in the 2009–2010 flu season, when
A/British Columbia/RV1222/2009 emerged in the early spring [18, 19]. Accurate early prediction of the
dominant circulating strain is an essential and important task in influenza research.
Understanding the evolution of influenza viruses has benefited from phylogenetic reconstructions of
the hemagglutinin protein evolution [11,20]. In an alternative approach, Lapedes and Farber [21], followed
by Smith et al. [22], applied a technique called multidimensional scaling to study antigenic evolution of
influenza. Plotkin et al. clustered hemagglutinin protein sequences using the single-linkage clustering
algorithm and found that influenza viruses group into clusters [23].
Here, we present a low-dimensional clustering method that can detect the cluster containing an
incipient dominant strain for an upcoming flu season before the strain becomes dominant. The method
builds upon the dimensional projection technique used by Lapedes and Farber [21] and Smith et al. [22]
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2to characterize hemagglutination inhibition data. In this paper, we first study the evolution of 2009
A(H1N1) by an evolutionary path map which leads to a suggestion for the H1N1 vaccine strain. Then,
we introduce the low-dimensional protein sequence clustering method. We propose an influenza vaccine
selection procedure based on this sequence clustering. The procedure is demonstrated and tested in detail
using historical data. We show the performance of the method to predict the dominant H3N2 strain in
an upcoming flu season using data solely from before the flu season, on data since 1996. We compare the
results to those from existing methods since 1996. In the discussion section, we discuss the relationship
between the protein sequence clustering method and previous approaches. We discuss the false positive
rate, as well as other challenges.
Results
Evolutionary path of 2009 A(H1N1) influenza
We first construct the directional evolutionary path for the 2009 A(H1N1) influenza. We use high reso-
lution data in sequence, time, and world spatial coordinate to construct this evolutionary relationship.
Since its first detection, the 2009 A(H1N1) virus has been extensively sequenced [2, 3]. By May 1, 2009,
the number of confirmed cases reported by WHO was 333 [5]. At the same time, the sequenced hemag-
glutinin protein (HA) available in NCBI Influenza Resources Database were 312 [24]; that is to say most
of the confirmed cases at that time were sequenced. At July 1, 2009, the ratio of sequenced HA protein to
confirmed cases by WHO was 1039/77201 [5], a number which is still much larger than that for seasonal
flu. In addition, the Influenza Resources Database contains the date of collection of each 2009 A(H1N1)
virus strain. We reconstruct the evolutionary history of swine flu viruses with the following procedure. If
strain B is mutated from strain A, we term strain A “founder” and strain B “F1” We align the HA pro-
teins of all 2009 A(H1N1) strains. Then, for each strain, we find its founder strain based on the following
four criteria: 1, the founder strain should appear earlier than the strain, as judged by collection date; 2,
the founder strain should have only one amino acid difference in the HA1 protein relative to the F1 strain;
3, the founder should also have the most similar nucleotide sequence relative to F1; and 4, the founder
strain should have a large number of identical copies circulating in human population, as approximated
by the number of different strains with identical HA sequences in the Influenza Resources Database. By
applying these four criteria to 2009 A(H1N1) influenza, we construct the directional evolutionary path
map, as shown in Fig. 1. We can see two clusters: one around A/New York/19/2009 (#28), and another
one around A/Texas/05/2009 (#12). Most new strains are from the Northern hemisphere, and strains
from the Southern hemisphere are mainly located at the edge of the map, such as strain #96, #120, and
#126. Geographically, we see many founder to F1 links are from US and Mexico to other countries, but
we rarely see founder to F1 links that are from other countries to US and Mexico, or from other countries
to other countries except US and Mexico (see Materials and Methods). We also found that strains with
more F1 in Fig. 1 are more frequently seen in the human population. For example, in the Influenza
Resources Database, we found 153 strains to be identical with A/New York/19/2009, which has 29 F1
strains, and 120 strains to be identical with A/Texas/05/2009, which has 24 F1 strains. We can see in
Fig. 1 that A/Texas/05/2009 is at the very upstream of the map, with downward connections to most
of the other strains by direct or two-step links. This result agrees with the US Food and Drug Adminis-
tration [25] recommendation of A/Texas/05/2009 as a vaccination strain. The alternative vaccine strain
A/California/7/2009 (#7) has fewer F1 strains and it is not located at the center of the network.
Low-dimensional clustering
We use a low-dimensional clustering method to visualize the antigenic distance matrix of the viruses.
We use a statistical tool called “multidimensional scaling” [26]. This method was used by Lapedes
3and Farber [21] and Smith et al. [22] to project ferret hemagglutination inhibition assay data to low
dimensions. The influenza viral surface glycoprotein hemagglutinin is a primary target of the protective
immune response. Here we project the hemagglutinin protein sequence data, rather than animal model
data, to low dimensions. The HA1 protein of influenza with 329 residues can be considered as a 329-
dimension space. The multidimensional scaling method is applied to rescale the 329-dimension space to
a 2-dimensional space, so that we can plot and visualize it. First, we do a multialignment of the HA1
proteins. Then, the distance between any two proteins is calculated as
dij =
1
N
N∑
m=1
(1− δsi,m,sj,m) (1)
where si,m is the amino acid of protein i at position m. The term δsi,m,sj,m is 1 if amino acids of protein
i and j at position m are the same. Otherwise, it is 0. For the 2009 H1N1 viruses, we consider the entire
HA protein, and N = 566. For H3N2 viruses, we consider only the HA1 protein, and N = 329, because
the entire HA proteins are not completely sequenced in many cases. Thus, dij is the number of amino
acid differences between HA proteins normalized by length. The multidimensional scaling produces a
protein distance map, for example, Fig. 2(b). In this map, each data point represents a flu strain isolate.
The Euclidean distance between two points in the map approximates the protein distance in Equation
1 between these two flu strains (see Materials and Methods for details of this distance approximation
procedure). Two closely located points imply two strains with similar HA protein sequences.
We apply the low-dimensional clustering method to study 2009 A(H1N1). We plot the protein distance
map in Fig. 2(b). Both A/Texas/05/2009 and A/New York/19/2009 are located near the center of the
cluster, in good agreement with the observation from Fig. 1 that they are the founder strains for many F1
strains. To detect the clusters in the protein distance map, we use a statistical method known as kernel
density estimation [26]. Kernel density estimation is a non-parametric method to estimate the probability
density function from which data come. The kernel density figure is produced from the protein distance
map, and it shows the density of influenza strains in sequence space. We plot the kernel density as the
three dimensional shaded surface. For example, the kernel density surface Fig. 2(a) is produced from Fig.
2(b). The x and y axes in Fig. 2(a) are the same as that in Fig. 2(b) and are protein distance coordinates.
The z dimension measures the density of flu strains around point (x, y). We use the surface height and
the colors to represent z values, and the color is proportional to surface height. A peak in kernel density
Fig. 2(a) indicates a cluster of related flu strains in the protein distance map Fig. 2(b)
There are two significant clusters in the Fig. 2(a), as two peaks are observed. The cluster on the left
side contains A/Texas/05/2009. Another cluster on the right side contains A/New York/19/2009. The
2009 A(H1N1) virus has evolved slowly to date. The greatest pepitope antigenic distance (definition in the
Materials and Methods) between A/Texas/05/2009 and all sequenced strains is measured to be < 0.08.
Values of pepitope less than 0.45 for H1N1 indicate positive expected vaccine efficacy [27], and so a vaccine
is expected to be efficacious. All of the amino acids in all five epitopes of a strain of A/Texas/05/2009 and
a strain of A/New York/19/2009 are the same. Multidimensional scaling predicts that A/Texas/05/2009
will be the dominant strain in the 2009–2010 season, and that A/Texas/05/2009 is a suitable strain for
vaccination. Our focus is on the expected vaccine effectiveness, as it can be judged from antisera HI
assay or sequence data alone. We do not consider other aspects such as growth in hen’s eggs or other
manufacturing constraints. Laboratory growth and passage data are needed to address these aspects.
H3N2 virus evolution for 40 years
We construct the protein distance map to determine the evolution of influenza A(H3N2) virus from 1969 to
2007. Sequences of HA1 proteins were downloaded from the Influenza Virus Resources database [24]. We
use the multidimensional clustering method [21] to generate the protein distance map and corresponding
kernel density estimation in Fig. 3. Smith et al. [22] produced a similar graph using ferret antisera HI
4assay data. The figure presented here has a higher resolution, and more clusters are observed, because
protein sequences data are more abundant and accurate than antisera HI assay data. The evolution of
influenza tends to group strain into clusters. In Fig. 3, we identified 14 major clusters by setting a cutoff
value of kernel density. We marked each cluster by the first vaccine strain in the cluster. The average
duration time for a cluster is 2.7 years, which is also the approximate duration of a vaccine. There are
apparent gaps between clusters. The antigenic distance between two strains in two separate clusters is
larger than the distances within the same cluster. The influenza virus evolves within one cluster before
jumping from one cluster to another cluster. This dynamics occurs because small antigenic drift by one
or a few sequential mutations does not lead the virus to completely escape from cross immunity induced
by vaccine protection or prior exposure.
For vaccine design, when the viruses evolve as a quasispecies in the same cluster, the vaccine that
is targeted to the cluster provides protection. This protection decreases with antigenic distance. When
the viruses jump to a new cluster by antigenic drift or shift, one would want to update the vaccine to
provide protection against strains in the new cluster. In Fig. 3(a), the arrows point to the exact position
of vaccine strains. It can be seen that the positions of vaccine strains are near the center of clusters. It
can be shown mathematically that choosing the consensus strain of a cluster as vaccine strain minimizes
the pepitope antigenic distance between vaccine strain and cluster strains, and thus maximizes expected
vaccine efficacy.
Influenza vaccine strain selection
We now use the low-dimensional sequence clustering method in an effort to detect a new flu strain before
it becomes dominant. A question of interest in the influenza research is whether we can predict which
strain will be dominant in the next flu season based on the information we have at present. The WHO
gathers together every February to make a recommendation for influenza strains to be used in vaccine
for next flu season in the Northern hemisphere. The vaccine is expected to have high efficacy if the
chosen strain is dominant in the next flu season. The recommendation is especially challenging to make
when the dominant strain in next flu season has not been dominant before February of that year. For
example, in mid-March 2009, a new H3N2 strain appeared [18, 19], which infected a significant fraction
of the population in the Southern hemisphere.
The current accepted influenza vaccine strain selection procedure is as follows [17]. Isolates samples are
collected by WHO GISN and are characterized antigenically using the hemagglutination inhibition(HI)
assay. About 10% of samples are also sequenced in HA1 domain of HA gene. Antigenic maps are
constructed from the HI assay data using dimensional projection technique. Examination of HI data is
not dependent on analysis using dimensional projection, but rather, the primary HI data may carry the
most weight. If the vaccine does not match the current circulating strains, the vaccine is updated to
contain one representative of the circulating strains. The emerging variant strains are identified. If the
antigenically distinct emerging variants are judged to be the dominant strains in the upcoming season,
the vaccine is updated to include one representative of emerging variants. The key issue and major
difficulty is how to judge whether emerging variants will be the dominant variants in next season. If a
fourfold difference in antisera HI titer between the vaccine strain and the emerging strains is observed,
the emerging strain is to be determined to be dominant strains in upcoming season, and an updated
vaccine is recommended to include the emerging strains [17].
Here, we propose a modified vaccine selection process based on clustering detection. First, we apply
the multidimensional scaling to make a protein distance map from HA1 sequences, instead of construct-
ing an antigenic map from HI assay data. Then, we use kernel density estimation to determine the
clusters of strains. If the vaccine does not match the current circulating cluster, the vaccine is up-
dated to contain the current circulating strain. If the vaccine matches the current circulating cluster,
but an emerging cluster is judged likely to be the major cluster in the upcoming season, the vaccine
is updated to contain the consensus strain of the emerging cluster. We judge whether a cluster is an
5emerging dominant cluster by two criteria. The first criterion is that this cluster can be detected by
kernel density estimation, and is separate from the cluster that contains the current circulating strain
or vaccine strain. A cluster that can be detected by kernel density estimation usually contains a cen-
tral strain that has multiple identical copies and some F1 strains that are closely related to the central
strain. An example is the cluster of A/Texas/05/2009(H1N1) in Fig. 1. A/Texas/05/2009(H1N1) is
the central strain, which has 120 strains with identical HA protein sequences in the Influenza Virus Re-
source database [24]. A/Texas/05/2009(H1N1) also has 29 F1 strains with one amino acid different. So,
A/Texas/05/2009(H1N1) and the surrounding strains form a cluster as we detected in Fig. 2 by kernel
density estimation.
The second criterion is that the current vaccine strain does not match the consensus strain of the
cluster and is estimated to provide low protection against strains in the cluster. That is, an immune
response stimulated by a vaccine cannot effectively protect against infection by sufficiently distant by
new strains. The consensus strain is a protein sequence that shows which residues are most abundant in
the multialignment at each position. The efficacy of current vaccine to the new cluster can be estimated
from ferret antisera HI assay data. However, the antisera data has low resolution and has an imperfect
correlation to vaccine effectiveness in humans [16, 28]. Instead, we use pepitope, which is calculated as
the fraction of mutations in dominant epitope, to estimate vaccine efficacy and which has a more robust
correlation to vaccine effectiveness in human than do ferret HI data [16]. When the pepitope between the
current vaccine strain and consensus strain of the new cluster is larger than 0.19, expected vaccine efficacy
decreases to 0 for H3N2 influenza, and the current vaccine cannot be expected to provide protection from
new strains. As the examples shown below, our method can detect an incipient dominant strain at its
very early stage, and the method appears to require about 10 sequences in the new cluster for detection.
Demonstration of low-dimensional sequence clustering method.
We demonstrate the method of detecting the A/Fujian/411/2002(H3N2) strain. The A/Panama/2007/1999
had been the vaccination strain for four flu seasons between 2000 and 2004 in the Northern hemisphere.
The vaccine strain was replaced by A/Fujian/411/2002(H3N2) in the 2004-2005 flu season, as described
in Table 1. The vaccine strain in the 2003-2004 season was A/Panama/2007/1999, while the dominant
circulating strain became A/Fujian/411/2002(H3N2). This mismatch resulted in a large decrease in vac-
cine efficacy in the 2003-2004 flu season [16]. The vaccine efficacy is estimated to be only 12% [29]. We
test whether our method can detect A/Fujian/411/2002(H3N2) as an incipient dominant strain before
it actually became dominant. We use only virus sequence data before October 1, 2003. We did not use
any virus data collected in 2003-2004 season. Therefore, our prediction and results are made without any
knowledge from what happened in the 2003-2004 season. We plot the protein distance map of the 2001-
2002 flu season in Fig. 4(d). To detect the clusters, we plot the kernel density in Fig. 4(b) for the data
in Fig. 4(d). There are two separate significant clusters. The one with the largest kernel density on the
left contains the current dominant strain A/Panama/2007/1999 and the widespread A/Moscow/10/1999
strain. The smaller one on the right is a new cluster, which contains A/Fujian/411/2002. Using the data
as of September 30, 2002, we seek to determine whether the new cluster on the right in Figs. 4(b) and
(d) will be the next dominant strain after A/Panama/2007/1999. We determine whether this cluster
fulfills the two criteria above. First, this new cluster can be significantly detected by kernel density
estimation. This cluster is separate from the current dominant strain, as we can see in figure. Second,
we calculated the average pepitope of the new cluster on the right with regard to A/Moscow/10/1999,
A/Panama/2007/1999 and A/Fujian/411/2002 to be 0.214, 0.1214, and 0.083, respectively. This means
the current vaccine contains A/Moscow/10/1999 is expected to provide little protection against viruses
in the new cluster. This result makes the new cluster fulfill the second criterion. Thus, we predict based
on the data as of September 30, 2002, that the cluster on the right in Fig. 4(d) will be the next dominant
cluster. This prediction was made on data collected one year earlier than when the A/Fujian/411/2002
became dominant in the 2003-2004 season. To further support our prediction, in Fig. 4(c), we plot the
6protein distance map from October 1, 2002, to February 1, 2003, right before the WHO selected the
vaccine strain for 2003-2004 season. To detect the clusters, we plot the kernel in Fig. 4(a) for the data in
Fig. 4(c). There are two separate major clusters observed in the kernel density estimation in Fig. 4(a).
The left cluster has the current dominant strain of A/Panama/2007/1999 and also A/Moscow/10/1999.
The right cluster has the A/Fujian/411/2002. We calculated the average pepitope of the right new clus-
ter with regards to A/Moscow/10/1999, A/Panama/2007/1999, and A/Fujian/411/2002 to be 0.2725,
0.1811, and 0.0367 respectively. This result further supports the prediction that the new cluster will
become dominant, and A/Fujian/411/2002, which is the most frequent strain in the new cluster, will be
or is very close to the next dominant strain. This suggestion proceeds the vaccine component switch by
1-2 years, as shown in Table 1.
Prediction for H3N2 influenza in 2009–2010.
By applying our method to the 2008-2009 flu season, we predict that the dominant H3N2 strain in
the 2009–2010 flu season may switch. Based on the flu activity in the 2008-2009 flu season, the WHO
made the recommendation in February 2009 that A/Brisbane/10/2007(H3N2) should be used as the
vaccine [30]. However, a new strain evolved just after the recommendation was published. The British
Columbia Center for Disease Control detected a new virus strain [18, 19] with 3 mutations in antigenic
sites (two in epitope B and one in epitope D). Since this new strain is relatively far from the vaccine
strain, with pepitope = 0.095, vaccine efficacy is expected to decrease to 20% [1, 16]. However, since the
mutations in this new strain “do not fulfill the criteria proposed by Cox as corresponding to meaningful
antigenic drift” [18, 31], and this strain still remained the minority of H3N2 viruses in July 2009, health
authorities were not certain that this new strain would replace the current dominant strain in 2009–2010
flu season. We use our method to investigate whether this new strain will be the next dominant strain.
We construct the protein distance map as shown in Fig. 5(c). We plot the kernel density estimation
in Fig. 5(a) for data in Fig. 5(c). By the data up to June 14, 2009, we see two major clusters in Fig.
5(a). The larger one on the right contains the current dominant strain A/Brisbane/10/2007, and the
left one is a new cluster which contains A/British Columbia/RV1222/2009. It is apparent that this new
cluster is separate from the current dominant cluster. Thus, this cluster fulfills the first criterion. We
calculated the average of pepitope of strains in the left new cluster with regards to A/Brisbane/10/2007
and A/British Columbia/RV1222/2009 to be 0.103 and 0.042 respectively. The vaccine that contains
A/Brisbane/10/2007 has an expected efficacy of 20% to the virus strains in the new cluster. Thus,
this new cluster satisfies both two criteria, and so we predict that this cluster which contains A/British
Columbia/RV1222/2009 will be the dominant cluster in the 2009–2010 season. The earliest time for us
to make this prediction is March 30, 2009. In Fig. 5(d) and (b), we already see this new cluster on the
left side of figure, though since there are only about 10 sequences in the new cluster, the kernel density of
this new cluster is smaller than that in the dominant cluster. This strain was mentioned as a concern on
5 May 2009, although by conventional methods the strain was not considered a potentially new dominant
strain in July 2009 [18]. With the method of the present paper, this new cluster is suggested earlier using
the data as of March 30, 2009.
Comparison with previous results.
Here we present a historical test of the method. For each flu season in the North Hemisphere from 1996,
we use only the H3N2 sequences data until February 1, before WHO published the recommendation
for vaccine. We use the low dimensional clustering to made the prediction for the dominant strain.
The conventional method as used by WHO is phylogenetic analysis combined with ferret antisera HI
assay. In Table 1, we compare the method with the conventional method. In the most recent 14 flu
seasons, influenza subtype H3 was dominant in 10. The WHO H3N2 vaccine component matches the
circulating strains in 8 seasons. Our predictions match the circulating strains in 9 seasons. In 1997-1998
7season, a novel flu strain Sydney/5/97 was found in June 1997. Because no similar strains were collected
before February 1, neither of the two methods can predict it. In 2003-2004 season, our method predicts
Fujian/441/2002 as the dominant strain, while phylogenetic analysis combined with ferret antisera HI
assay did not. For all other 8 seasons dominated by influenza subtype H3, the predictions of both
methods matched the dominant circulating strain. The 2009–2010 influenza season was dominated by
H1N1. But data from local outbreaks of H3N2 infections [18, 19] showed that the dominant H3N2
strain was A/British Columbia/RV1222/2009, as predicted in Table 1, rather than the vaccine strain
A/Brisbane/10/2007. For the 2010-2011 season, we recommend A/British Columbia/RV1222/2009 as a
vaccine strain, and the WHO recommended A/Perth/16/2009. These two strains are in the same cluster
and antigenically similar with a small pepitope = 0.048. Although these two strains are slightly different,
the vaccine is expected to be effective.
Detecting A/Wellington/1/2004 in the 2004 flu season in the Southern hemi-
sphere
The low-dimensional clustering can also be applied to influenza in the Southern hemisphere. As an
example, we test our method on the 2004 flu season. The recommended H3N2 vaccine strain by WHO used
in the 2004 flu season in the Southern hemisphere was A/Fujian/411/2002. Data from the surveillance
network suggested that the circulating dominant flu strain in the 2004 season in Southern hemisphere
was A/Fujian/411/2002, and a late surge of A/Wellington/1/2004 was also observed. For example,
in Argentina, a study showed that about 50% of infections were closely related to A/Fujian/411/2002
and another 50% were closely related to A/Wellington/1/2004 [32]. In New Zealand, the dominant
flu strain was A/Fujian/411/2002 which caused 78% of flu infections [33], and a late season surge of
A/Wellington/1/2004 was also reported [34]. Therefore, the vaccine recommended by WHO matches
the dominant strain and would be expected to have vaccine efficacy in the 2004 season in Southern
hemisphere.
We here use the low-dimensional clustering method to detect the A/Wellington/1/2004 strain, which
is not the major dominant strain but caused significant infections in the 2004 flu season. We plot the
protein distance and kernel density estimation for the H3N2 viruses in Fig. 6(d) and 6(b). We use the
data only as of February 1, 2004, 3 months prior to the 2004 flu Southern hemisphere season, which is
usually from May to September. We observed two clusters. The major cluster on the left side of Fig. 6(d)
is A/Fujian/411/2002-like, which was the vaccine strain in 2004 season. There is a new cluster in the right
side of Fig. 6(d) which contains A/Wellington/1/2004. The pepitope of A/Wellington/1/2004 with regards
to A/Fujian/411/2002 is 0.118. Therefore, we predict that A/Wellington/1/2004 will infect a large frac-
tion of the population, and the A/Fujian/411/2002 vaccine is expected to provide only partial protection
against the A/Wellington/1/2004 virus. However, since the appearance of A/Wellington/1/2004 was just
before the the 2004 flu season, it did not have sufficient time to spread out and become the dominant
strain in the 2004 flu season. From our observation, it usually takes about 8 months or longer for a new
strain to become dominant after its appearance in a new cluster. Therefore, the predominant flu strain in
2004 season is expected to be A/Fujian/411/2002 based on the data as of February 1, 2004. This result
agrees with the dominant flu strain in the 2004 flu season.
Detecting A/California/4/2004 as a future dominant strain
As a further example of applying the low-dimensional clustering method to influenza in Southern hemi-
sphere, we test the method on the 2005 flu season. The recommended H3N2 vaccine strain in the 2005 flu
season in the Southern hemisphere was A/Wellington/1/2004. Data from HI assay tests and surveillance
suggest that the dominant H3N2 strain in the 2005 season was A/California/7/2004. In HI tests with
postinfection ferret sera the majority of influenza A(H3N2) viruses from February 2005 to October 2005
were closely related to A/California/7/2004, as reported by WHO on October 7, 2005 [35]. Surveillance
8data from Victoria, Australia, show that 45% of influenza A infections were A/California/7/2004-like
(H3), 11% were A/Wellington/1/2004 (H3) and 44% were A/New Caledonia /20/99-like (H1), as col-
lected in the 2005 flu season [36]. Surveillance data from New Zealand also show that the dominant H3N2
strain in the 2005 flu season was A/California/7/2004 [37].
We plot the protein distance for the H3N2 viruses in the 2003-2004 flu season in Fig. 6(c). We only
use the data as of September 30, 2004, earlier than the October 2004 date when the WHO published
the influenza vaccine recommendation for Southern hemisphere. We plot the kernel density estima-
tion in Fig. 6(a) for the data in Fig. 6(c). There are three major clusters in Fig. 6(a). The one on
the left is the current dominant cluster which are mostly A/Fujian/422/2002-like viruses. There is a
middle cluster centered on A/Wellington/1/2004. The one on the right contains A/California/7/2004.
Both the A/California/7/2004 cluster and the A/Wellington/1/2004 cluster are antigenically novel from
A/Fujian/411/2002.
When the protein distance map and kernel estimation as of February 1, 2004, is plotted in Fig. 6(d)
and (b), we still see the A/Wellington/1/2004 cluster. With these data, the A/California/7/2004 cluster is
no longer observed. Thus, A/California/7/2004 cluster is a newly appearing cluster and we consider it to
be the emerging strain. The new cluster which contains A/California/7/2004 is separate from the current
dominant cluster. We calculated the average pepitope of the new cluster that contains A/California/7/2004
with regard to A/Fujian/411/2002 to be 0.112. This makes the new cluster fulfill both criteria for an
incipient dominant strain cluster. So we predict based on the information as of September 30, 2004, that
A/California/7/2004 will be the next dominant strain after A/Fujian/411/2002 in Southern hemisphere.
We further predict from these data that A/California/7/2004 will be the dominant strain in the following
flu season in the Northern hemisphere. These predictions agree with the observed dominant strain in the
2005 flu season.
Discussion
The evolution of influenza virus is driven by cell receptor distributions, non-specific innate host defense
mechanisms, cross immunity [10,11], and other contributions to viral fitness. In this paper, we focused on
HA protein evolution under antibody selection pressure. The degree to which the immunity induced by
one strain protects against another strain depends on their antigenic distance [16]. Because the human
immune response to viral infection is not completely cross protective, natural selection favors amino-acid
variants of the HA protein that allow the virus to evade immunity, infect more hosts, and proliferate.
Mutant strains surround the dominant strain and group into a cluster rather than evolve in a defined
direction [22,23]. After the virus has circulated in population for one or more years, effective vaccines and
cross immunity of the population drive the evolution of influenza by mutation and reassortment. This
evolution increases the immune-escape component of the fitness of new strains, and eventually causes a
new epidemic. These new immune-escape strains will form a new cluster, and the old clusters will die
out, thus starting a new cycle. This process of creating of new clusters is what our method detects.
The low dimensional clustering can be used not only in genetic sequences but also on distances
calculated from inhibition assays of antibody and antigens, as developed by Lapedes and Farber [21]
and Smith et al. [22]. The inhibition assay provides an approximation of antigenic distance and is
broadly used as a marker for vaccine efficacy. The inhibition assay suffers from low resolution of data,
which multidimensional scaling improves, and is less able to predict the vaccine efficacy than the pepitope
method [16]. The genetic sequences used here are a direct description of the evolution of pathogen
and antigenic distance of influenza. To aid vaccine selection, the low dimensional clustering on genetic
sequences appears informative.
Challenges may arise in application of the method described here. If two or more new clusters appear
in one season, additional information is needed to decide which cluster should be chosen for vaccine.
Fortunately, it has been shown that the evolution of influenza is typically in one direction [11, 22]. It is
9rare to have two or more new clusters in the protein distance map in one season. As experience with the
low dimensional sequence clustering is gained, it may be that cluster structure will allow more precise
prediction of vaccine efficacy. Despite these issues, the method described here can assist the design of
vaccines, and it provides a new tool to analyze influenza viral dynamics. We did not see any false positive
results in Table 1.
The current WHO method works quite well in many years. The method discussed here appears to
offer an additional tool which may provide additional utility.
Materials and Methods
Data sources
Influenza hemagglutinin A(H3N2) sequences before October 1, 2008, and A(H1N1) sequences as of De-
cember 5, 2009, were downloaded from NCBI Influenza Virus Resources [24]. All hemagglutinin sequences
used in our study are filtered by removing identical sequences, Thus, all groups of identical sequences in
the dataset are be represented by the oldest sequence in each group. This approach reduces the number
of sequences by keeping only the unique sequences in the dataset. The hemagglutinin proteins of 2009
A(H1N1) used in our work are listed in Supplementary Table 3. The numerical labels in Figs. 1 and 2
are the same as the labels in the first column of Supplementary Table 3. Influenza A(H3N2) sequences
after October 1, 2008, were downloaded from GISAID database, see Supplementary Table 6. GISAID
has the latest H3N2 sequence data.
Geographical spread pattern of 2009 A(H1N1)
It is believe that the 2009 A(H1N1) virus was most likely originated from Mexico [3]. It first spread to
the neighboring country USA and then to other countries. We display this geographical spread pattern
in Fig. 1. We take the founder-F1 relationship from Fig. 1, and assume the virus spreads from location of
founder to the location of F1. We consider three regions: USA, Mexico and other countries except USA
and Mexico. Then we count the cases of spreading from one region to another region. In Supplementary
Table 2, we show that we observed many more paths of spreading from the USA to other countries than
from other countries to the USA. The major path of spreading is from USA to other countries. This result
indicates our directional evolutionary map of Fig. 1 is in good agreement with the pattern of geographical
spread.
Multidimensional scaling
The goal of multidimensional scaling is to represent the distance of proteins by a Euclidean distance in
coordinate space. We calculate the distance between proteins i and j, dij , by the number of amino acid
residue differences divided by the total number of amino acid residues, as defined by Equation 1 in the
main text. To do multidimensional scaling, we start with the distance of the proteins. The object of
multidimensional scaling is to find the two, or p in general, directions that best preserve the distances
dij between the N proteins
F =
N∑
i,j=1
(dij −Dij)2 (2)
Here, Dij = ‖xi − xj‖ is the Euclidean distance between proteins i and j in the projected space, and
‖ • ‖ is the vector norm. The algorithm is as follows. Let the matrix A = [(aij)], where aij = − 12d2ij . The
eigenvalues of A are γ1, γ2, ..., γN and γ1 ≥ γ2 ≥ ... ≥ γN . Let V (1) = (v(1)1 , v(1)2 , ..., v(1)N ) be the eigenvector
of γ1 and V
(2) = (v
(2)
1 , v
(2)
2 , ..., v
(2)
N ) be the eigenvector of γ2. Let x =
√
γ1V
(1) and y =
√
γ2V
(2). The two
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coordinates in Figs. 2–6 are x and y. The x-axis in the protein distance map is the largest eigenvector.
We take H3N2 2008–2009 season as an example. In Fig. 5(c), we observe two clusters. One cluster is
on the right side of figures with x value positive and another one has negative x values. We define the
consensus sequence of a group of flu strains by taking the most frequent amino acid at each position. We
calculate the consensus sequences both for the strains in the cluster on the right and on the left of figure.
We found amino acids at four positions (76, 160, 172, 203) are different for these two consensus H3N2
strains, see Supplementary Table 1. Interestingly, the Shannon entropy calculated from all 2008–2009
season sequences at these four positions (0.43, 0.67, 0.59, 0.50) are the largest, which means the diversity
at these four position are the largest.
There is software available to run the multidimensional scaling. We use the Matlab function “CMD-
SCALE” to generate an N × p configuration matrix Y . Rows of Y are the coordinates of N points in
p-dimensional space. The “CMDSCALE” also returns a vector E containing the sorted eigenvalues of
what is often referred to as the “scalar product matrix,” which, in the simplest case, is equal to YY>. If
only two or three of the largest eigenvalues E are much larger than others, then the matrix D based on
the corresponding columns of Y nearly reproduces the original distance matrix d. We used the influenza
H3N2 in 2001–2002 season as an example. The five largest of all 180 eigenvalues are 0.0361, 0.0032,
0.0024, 0.0020, 0.0016. The first two largest eigenvalues contribute 70% to the sum of all 180 eigenvalues,
which indicates p = 2. Then, we plot the the N points in a two-dimensional graph. Each point represents
a protein. The Euclidean distance between any two points Dij on the graph should be equal to or close
to the distance of these two proteins. that is, Dij ≈ dij . As an example, in Supplemental Fig. 1, We
show that Dij and dij have a strong linear relationship. A short MATLAB program of multidimensional
scaling is as follow.
% Multidimensional scaling.
% alignment.aln is a sequence multialignment file
% generated by software ClustalW.
clear
Sequences = multialignread(’alignment.aln’);
distances = seqpdist(Sequences,’Method’,’p-distance’);
Y = cmdscale(distances);
scatter(Y(:,1), Y(:,2));
pepitope estimation
The value of pepitope is a measure of antigenic distance between influenza A vaccine and circulating
strains. The hemagglutinin protein has five epitopes. The dominant epitope for a particular circulating
strain in a particular season was taken as that which had the largest fractional change in amino acid
sequence relative to the vaccine strain. The value of pepitope is defined as the fraction of number of
amino acid differences in the dominant epitope to total number of amino acids in the dominant epitope.
The antigenic distance between the vaccine strain and the circulating strain is quantified by pepitope.
By a metaanalysis of historical vaccine efficacy data from over 50 publications, Gupta et al. showed in
a metaanalysis that the pepitope between vaccine strain and circulating strain correlates well with the
vaccine efficacy, with R2 > 0.8 [16]. The value of pepitope can be easily calculated from sequence data.
Biases in the data
There are two biases in the sequence data. First, more isolates are sequenced in recent years. Generally
speaking, more sequences make the vaccine selection based on low-dimensional clustering methods more
reliable. That is why we compared low-dimensional clustering methods with WHO results only since
1996 in Table 1. To avoid these biases in the generation of the figure of evolution history of influenza for
the 40 years (Fig. 3), we choose 20 random isolates for each season, even though the database contains
11
more sequences in recent years. Second, most isolates are collected in USA. We found that many isolates
collected in USA are identical, because of the high sampling rate in USA. To reduce this bias, we collapse
redundant strains, keeping only distinct strains.
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Figure 1. The evolutionary path of 2009 A(H1N1) influenza. Strain #1: A/California/05/2009. Strain
#2: A/California/04/2009. Strain #7: A/California/07/2009. Strain #12: A/Texas/05/2009. Strain
#28: A/New York/19/2009. For complete strain names, see supplemental material. Strains from the
Northern and Southern hemisphere are shown as red dots and blue dots respectively. One branch
represents one substitution in the amino acid sequence.
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Figure 2. (a), Kernel density estimation for the protein distance map of 2009 A(H1N1) influenza as of
December 5, 2009. (b), The protein distance map of 2009 A(H1N1) influenza. The vertical and
horizontal axes of both figures represent protein distance as defined in Equation 1. A 0.0018 unit of
protein distance equals one substitution in the HA protein sequence of H1N1. The height and colors in
(a) both represent the density of isolates.
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Figure 3. (a) The protein distance map and (b) corresponding Kernel density estimation of influenza
from 1968 to 2007. The vertical and horizontal axes of both figures represent protein distance as defined
in Equation 1. A 0.0030 unit of protein distance equals one substitution in the HA1 protein sequence of
H3N2. The colors in (a) represent the time of collection of the isolates. The colors and height in (b)
represent the density of isolates. Each cluster is named after the first vaccine strain in the cluster.
HK68: Hongkong/1/68, EN72: England/42/72, VT75: Victoria/3/75, TX77: Texas/1/77, BK79:
Bangkok/1/79, PP82: Philippines/2/82, SC87: Sichuan/2/87, BJ89: Beijing/32/92, SD93:
Shandong/9/93, JB94: Johannesburg/33/94, WH95: Wuhan359/95, SN97: Sydney/5/97, PM99:
Panama/2007/99, FJ02: Fujian/411/2002;
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Figure 4. (a) Kernel density estimation and (c) protein distance map for H3N2 viruses between
October 1, 2002 and February 1, 2003. (b) Kernel density estimation and (d) protein distance map for
H3N2 viruses between October 1, 2001, and September 9, 2002. We plot a dotted line to separate the
two clusters. The vertical and horizontal axes of all figures represent protein distance as defined in
Equation 1. A 0.0030 unit of protein distance equals one substitution of the HA1 protein sequence of
H3N2.
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Figure 5. (a) Kernel density estimation and (c) protein distance map for H3N2 viruses from October
1, 2008, to June 14, 2009. (b) Kernel density estimation and (d) protein distance map for H3N2 viruses
between October 1, 2008, and March 30, 2009. The vertical and horizontal axes of all figures represent
protein distance as defined in Equation 1. A 0.0030 unit of protein distance equals one substitution of
the HA1 protein sequence of H3N2.
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Figure 6. (a), Kernel density estimation for the protein distance map for H3N2 viruses between
10/01/2003 and 09/30/2004. (b), Kernel density estimation for the protein distance map for H3N2
viruses between 10/01/2003 and 02/01/2004. (c), Protein distance map for H3N2 viruses between
10/01/2003 and 09/30/2004. We plot a dotted line to separate the two clusters. (d), Protein distance
map for H3N2 viruses between 10/01/2003 and 02/01/2004. The vertical and horizontal axes of all
figures represent protein distance. A 0.0030 unit of protein distance equals one mutation of the HA1
protein sequence of H3N2.
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Table 1. Summary of results
Flu season Vaccine strain Our prediction Circulating Circulating
from WHO [30] H3N2 strain subtype
1996-1997 Wuhan/359/95 Wuhan/359/95 Wuhan/359/95 H3
1997-1998 Wuhan/359/95 Wuhan/359/95 Sydney/5/97 H3
1998-1999 Sydney/5/97 Sydney/5/97 Sydney/5/97 H3
1999-2000 Sydney/5/97 Sydney/5/97 Sydney/5/97 H3
2000-2001 Panama/2007/1999 Panama/2007/1999 N/A H1
2001-2002 Panama/2007/1999 Panama/2007/1999 Panama/2007/1999 H3
2002-2003 Panama/2007/1999 Fujian/411/2002 N/A H1
2003-2004 Panama/2007/1999 Fujian/411/2002 Fujian/411/2002 H3
2004-2005 Fujian/411/2002 Fujian/411/2002 Fujian/411/2002 H3
2005-2006 California/7/2004 California/7/2004 California/7/2004 H3
2006-2007 Wisconsin/67/2005 Wisconsin/67/2005 Wisconsin/67/2005 H3
2007-2008 Wisconsin/67/2005 Wisconsin/67/2005 N/A H1
2008-2009 Brisbane/10/2007 Brisbane/10/2007 Brisbane/10/2007 H3
2009-2010 Brisbane/10/2007 BritishColumbia/RV1222/09 BritishColumbia/RV1222/09 H1
2010-2011 Perth/16/2009 BritishColumbia/RV1222/09 N/A N/A
This table includes the H3N2 vaccine strains, our prediction of dominant strains, the reported domi-
nant circulating H3N2 strains [38–53], and the circulating subtypes in the northern hemisphere [38–53].
Circulating H3N2 strains are absent if the dominant subtype is H1 or influenza B. The reported
dominant H3N2 strains and circulating subtypes data are from WHO Weekly Epidemiological Record
(http://www.who.int/wer/en/).
1Low-dimensional clustering detects incipient dominant influenza
strain clusters
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Figure 1. Plot of Euclidean distances of proteins as in Figure 4(d) of main text on x-axis and plot of
distance of corresponding proteins in y-axis. Closeness to the diagonal measures fidelity of the low
dimensional projection. A 0.0030 unit of protein distance equals one mutation of the HA1 protein
sequence of H3N2.
3Spreading path Number of cases
USA to Others 32
Others to USA 1
Mexico to Others 1
Others to Mexico 0
Others to others 6
Table 1. The geographical spread pattern of 2009 A(H1N1). ”Others” refers to other countries except
USA and Mexico.
4Position in HA1 protein of H3N2 76 160 172 203
Amino acid in consensus strain 1 Glu Asn Lys Asn
hline Amino acid in consensus strain 2 Lys Lys Asn Lys
Shannon Entropy 0.43 0.67 0.59 0.50
Table 2. Consensus strain 1 is the calculated from all strains in the cluster on the right side of Figure
5(c). Consensus strain 2 is the calculated from all strains in the cluster on the left side of Figure 5(c).
5Table 3. The 2009 A(H1N1) (swine flu) sequences in Figure 1. Data are from NCBI Influenza Virus
Resources.
Label Accession number Country Collection date Virus name
(mm/dd/yyyy)
1 ACP41926 USA 3/30/2009 A/California/05/2009
2 ACP41105 USA 4/1/2009 A/California/04/2009
3 ACR09364 Mexico 4/2/2009 A/Mexico/4108/2009
4 ACR09372 Mexico 4/2/2009 A/Mexico/3955/2009
5 ACQ99613 Mexico 4/2/2009 A/Mexico/4108/2009
6 ACP44189 USA 4/9/2009 A/California/07/2009
7 ACP41953 USA 4/9/2009 A/California/07/2009
8 ACT36657 USA 4/14/2009 A/Texas/04/2009
9 ACR49285 USA 4/14/2009 A/Texas/04/2009
10 ACU29959 USA 4/15/2009 A/San Antonio/PR922/2009
11 ACQ83310 USA 4/15/2009 A/Texas/15/2009
12 ACP41934 USA 4/15/2009 A/Texas/05/2009
13 ACQ99610 Mexico 4/19/2009 A/Mexico/4603/2009
14 ACR09375 Mexico 4/20/2009 A/Mexico/4635/2009
15 ACR67180 USA 4/21/2009 A/California/13/2009
16 ACT36662 USA 4/22/2009 A/California/12/2009
17 ACQ76383 USA 4/22/2009 A/Indiana/09/2009
18 ACR67176 USA 4/23/2009 A/Texas/10/2009
19 ACU29969 USA 4/23/2009 A/San Antonio/PR923/2009
20 ACR18983 USA 4/24/2009 A/Kansas/03/2009
21 ACR18990 USA 4/24/2009 A/New York/31/2009
22 ACR18980 USA 4/24/2009 A/Texas/08/2009
23 ACQ63286 USA 4/24/2009 A/Ohio/07/2009
24 ACQ73385 Canada 4/24/2009 A/Canada-NS/RV1535/2009
25 ACQ76340 USA 4/24/2009 A/Kansas/03/2009
26 ACQ76386 USA 4/24/2009 A/Ohio/07/2009
27 ACR49292 USA 4/24/2009 A/California/11/2009
28 ACP44147 USA 4/25/2009 A/New York/19/2009
29 ACT36665 USA 4/25/2009 A/New York/45/2009
30 ACQ63209 USA 4/25/2009 A/New York/12/2009
31 ACR18986 USA 4/25/2009 A/New York/11/2009
32 ACR18987 USA 4/25/2009 A/New York/09/2009
33 ACR18994 USA 4/25/2009 A/New York/12/2009
34 ACR67173 USA 4/25/2009 A/New York/35/2009
35 ACR67169 USA 4/26/2009 A/South Carolina/10/2009
36 ACQ76333 USA 4/26/2009 A/South Carolina/09/2009
37 ACQ76362 USA 4/26/2009 A/Arizona/02/2009
38 ACR49284 USA 4/26/2009 A/South Carolina/09/2009
39 ACR08534 USA 4/27/2009 A/Texas/23/2009
40 ACR08429 USA 4/27/2009 A/New York/3012/2009
41 ACR08526 USA 4/27/2009 A/Florida/04/2009
42 ACR49289 USA 4/27/2009 A/Arizona/04/2009
43 ACR38825 USA 4/27/2009 A/Georgia/01/2009
644 ACR18991 USA 4/27/2009 A/Washington/12/2009
45 ACT68105 Mexico 4/27/2009 A/Mexico/InDRE13547/2009
46 ACQ84467 USA 4/27/2009 A/New York/1682/2009
47 ACR67194 USA 4/28/2009 A/Delaware/08/2009
48 ACR15621 United Kingdom 4/28/2009 A/England/195/2009
49 ACR49294 USA 4/28/2009 A/Delaware/05/2009
50 ACS94554 USA 4/28/2009 A/Delaware/06/2009
51 ACS94543 USA 4/28/2009 A/Delaware/07/2009
52 ACR56450 USA 4/28/2009 A/New York/3199/2009
53 ACT33094 Germany 4/29/2009 A/Bayern/62/2009
54 ACT68103 Mexico 4/29/2009 A/Mexico/InDRE13494/2009
55 ACR43957 France 4/29/2009 A/Paris/2573/2009
56 ACR67179 USA 4/30/2009 A/Kentucky/05/2009
57 ACR43939 France 4/30/2009 A/Paris/2590/2009
58 ACR39453 USA 4/30/2009 A/New York/3232/2009
59 ACR18920 Hong Kong 4/30/2009 A/Hong Kong/01/2009
60 ACT36664 USA 4/30/2009 A/California/19/2009
61 ACT36651 USA 4/30/2009 A/Tennessee/07/2009
62 ACR81633 France 5/1/2009 A/Paris/2591/2009
63 ACS27239 USA 5/1/2009 A/New York/3307/2009
64 ACU13100 USA 5/1/2009 A/California/27/2009
65 ACT36660 USA 5/1/2009 A/California/20/2009
66 ACR67178 USA 5/4/2009 A/Vermont/03/2009
67 ACU13096 USA 5/5/2009 A/Texas/30/2009
68 ACS72650 USA 5/5/2009 A/Michigan/05/2009
69 ACS78026 USA 5/6/2009 A/New York/3351/2009
70 ACS91400 France 5/6/2009 A/Strasbourg/2611/2009
71 ACT68109 Canada 5/7/2009 A/Canada-QC/RV1759/2009
72 ACT68111 Canada 5/8/2009 A/Canada-SK/RV1793/2009
73 ACR56352 Sweden 5/8/2009 A/Stockholm/29/2009
74 ACR32996 Finland 5/10/2009 A/Finland/553/2009
75 ACR38877 China 5/10/2009 A/Shandong/1/2009
76 ACS77996 USA 5/14/2009 A/New York/3463/2009
77 ACT86049 USA 5/16/2009 A/New York/3502/2009
78 ACR46991 Japan 5/16/2009 A/Osaka/1/2009
79 ACS91402 France 5/17/2009 A/Paris/2650/2009
80 ACS36645 China 5/18/2009 A/GuangzhouSB/01/2009
81 ACS72646 USA 5/19/2009 A/Arizona/09/2009
82 ACT68114 Canada 5/20/2009 A/Canada-MB/RV1964/2009
83 ACT82512 Brazil 5/20/2009 A/Sao Paulo/2056/2009
84 ACS34967 Japan 5/21/2009 A/Sakai/2/2009
85 ACT68117 Canada 5/21/2009 A/Canada-MB/RV1982/2009
86 ACR67262 Italy 5/21/2009 A/Milan/UHSR1/2009
87 ACU29999 Taiwan 5/22/2009 A/Taiwan/T1339/2009
88 ACS34968 Japan 5/22/2009 A/Shiga/1/2009
89 ACS27770 Russia 5/22/2009 A/Kaluga/01/2009
90 ACS91399 France 5/22/2009 A/Paris/2670/2009
791 ACR54964 China 5/23/2009 A/Zhejiang/1/2009
92 ACR67254 China 5/23/2009 A/Beijing/4/2009
93 ACT68101 Canada 5/24/2009 A/Canada-MB/RV2023/2009
94 ACR78588 Russia 5/26/2009 A/Moscow/IIV02/2009
95 ACS50088 Finland 5/26/2009 A/Finland/554/2009
96 ACT33123 Brazil 5/28/2009 A/Mato Grosso/2329/2009
97 ACU30009 Taiwan 5/28/2009 A/Taiwan/T1773/2009
98 ACT68118 Canada 5/28/2009 A/Canada-MB/RV2013/2009
99 ACT79625 China 5/28/2009 A/Shanghai/60T/2009
100 ACT82514 Brazil 5/29/2009 A/Sao Paulo/2261/2009
101 ACR83538 China 5/29/2009 A/Guangdong/03/2009
102 ACT21932 Sweden 5/29/2009 A/Stockholm/31/2009
103 ACS68822 China 5/31/2009 A/Zhejiang/2/2009
104 ACT21971 Sweden 6/1/2009 A/Stockholm/35/2009
105 ACS94551 USA 6/1/2009 A/Rhode Island/04/2009
106 ACS54262 Japan 6/2/2009 A/Tokushima/1/2009
107 ACS91398 France 6/2/2009 A/Paris/2722/2009
108 BAH95823 Japan 6/3/2009 A/Saitama/55/2009
109 ACS45035 USA 6/5/2009 A/California/04/2009
110 ACT79624 China 6/6/2009 A/Shanghai/143T/2009
111 ACT83737 Italy 6/8/2009 A/Ancona/01/2009
112 ACT10316 Hong Kong 6/11/2009 A/Hong Kong/2369/2009
113 ACT83738 Italy 6/11/2009 A/Ancona/02/2009
114 ACS92600 Japan 6/16/2009 A/Utsunomiya/1/2009
115 ACU17389 USA 6/17/2009 A/New York/4197/2009
116 ACT79183 USA 6/18/2009 A/Bethesda/SP508/2009
117 ACS45017 China 6/18/2009 A/Nanjing/1/2009
118 ACU30112 USA 6/18/2009 A/Silver Spring/SP509/2009
119 ACU30121 USA 6/18/2009 A/Silver Spring/SP510/2009
120 ACT22055 Chile 6/19/2009 A/Puerto Montt/Bio87/2009
121 ACU30073 Colombia 6/25/2009 A/Bogota/0466N/2009
122 ACU13129 China 6/29/2009 A/Changsha/78/2009
123 ACT79133 Japan 6/29/2009 A/Japan/1070/2009
124 ACT66162 Singapore 6/30/2009 A/Singapore/TLL01/2009
125 ACT83739 Italy 7/1/2009 A/Ancona/04/2009
126 ACT82516 Brazil 7/3/2009 A/Sao Paulo/43812/2009
127 ACT83741 Italy 7/12/2009 A/Ancona/05/2009
8Table 4. The H3N2 sequences in Figure 4(c). Data are from NCBI Influenza Virus Resources.
Label Accession number Country Collection date Virus name
(mm/dd/yyyy)
1 ACF36384 Hong Kong 10/1/2002 A/Hong Kong/CUHK50200/2002
2 ACC66393 Australia 10/2/2002 A/VICTORIA/432/2002
3 ABI92632 Australia 10/15/2002 A/Western Australia/36/2002
4 ACC67637 France 10/15/2002 A/LYON/19989/2002
5 ACC77932 USA 10/30/2002 A/Hawaii/HI-02-3736/2002
6 ACC66357 South Korea 10/31/2002 A/Kwangju/219/2002
7 ACC77933 USA 11/1/2002 A/New York/28/2002
8 ACC77934 Bulgaria 11/2/2002 A/Sofia/343/2002
9 ACC67720 Bulgaria 11/2/2002 A/SOFIA/344/2002
10 ACC66354 South Korea 11/14/2002 A/Incheon/260/2002
11 ACC66358 South Korea 11/18/2002 A/KYONGBUK/304/2002
12 ACC66369 South Korea 11/20/2002 A/Pusan/504/2002
13 ACC66345 South Korea 11/20/2002 A/Cheonnam/323/2002
14 ACC77936 China 11/21/2002 A/Beijing/178-NEW-AGN/2002
15 ACC77937 Philippines 11/21/2002 A/Philippines/PH-1159050/2002
16 ACC66344 South Korea 11/29/2002 A/Cheju/274/2002
17 ACC77939 China 12/1/2002 A/Anhui/550/2002
18 ACC67682 France 12/1/2002 A/PARIS/207/2002
19 ACC77940 USA 12/2/2002 A/Alaska/AK-RSP-02-753/2002
20 ACN32523 Italy 12/2/2002 A/Genoa/1/2002
21 ABO37625 South Korea 12/2/2002 A/Korea/770/2002
22 ACC77942 USA 12/3/2002 A/California/CA-T02-3025/2002
23 ACC66374 Singapore 12/7/2002 A/SINGAPORE/44/2002
24 ACC77944 Taiwan 12/9/2002 A/Taiwan/TW-1521/2002
25 ACC77945 Turkey 12/13/2002 A/Turkey/TU-RSP-02-1035/2002
26 ACC77946 Taiwan 12/15/2002 A/Taiwan/TW-1522/2002
27 ACF36415 Hong Kong 12/18/2002 A/Hong Kong/CUHK53123/2002
28 ACC77948 China 12/20/2002 A/Beijing/301/2002
29 ACC77949 USA 12/22/2002 A/Hawaii/HI-02-4051/2002
30 ACC67657 Latvia 12/23/2002 A/LATVIA/13794/2002
31 ACC77950 USA 12/24/2002 A/Hawaii/HI-02-4055/2002
32 ABO10182 Japan 12/25/2002 A/Kumamoto/102/2002E
33 ACC77951 USA 12/28/2002 A/Hawaii/HI-02-4092/2002
34 ACC77952 USA 12/29/2002 A/North Carolina/NC-C02-4981/2002
35 ACC66516 Singapore 1/7/2003 A/SINGAPORE/7/2003
36 ACC66445 United Kingdom 1/8/2003 A/ENGLAND/1/2003
37 ACC67602 USA 1/8/2003 A/Washington/WA-V130811/2003
38 ACC67661 Germany 1/14/2003 A/BAYERN/1/2003
39 ACC67377 Egypt 1/14/2003 A/Egypt/EG-2002923226/2003
40 ACC67440 USA 1/15/2003 A/Michigan/MI-VC76/2003
41 ACC66517 Singapore 1/15/2003 A/SINGAPORE/16/2003
42 ABO20960 Australia 1/15/2003 A/Sydney/015/03
43 ACC66485 USA 1/16/2003 A/MEMPHIS/1/2003
44 ACC66486 USA 1/16/2003 A/Memphis/2/2003
945 ACF36424 Hong Kong 1/18/2003 A/Hong Kong/CUHK5627/2003
46 ACF36426 Hong Kong 1/20/2003 A/Hong Kong/CUHK5723/2003
47 ABB03112 USA 1/20/2003 A/New York/485/2003
48 ACC67688 Ireland 1/24/2003 A/IRELAND/1215/2003
49 ACC66560 USA 1/28/2003 A/WYOMING/2/2003
50 ACC66521 Bulgaria 2/1/2003 A/SOFIA/141/2003
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Table 5. The H3N2 sequences in Figure 4(d). Data are from NCBI Influenza Virus Resources.
Label Accession number Country Collection date Virus name
(mm/dd/yyyy)
1 ABI92544 Australia 10/2/2001 A/Western Australia/17/2001
2 ACC66320 Australia 10/29/2001 A/South Australia/102/2001
3 ACF36383 Hong Kong 11/8/2001 A/Hong Kong/CUHK50080/2001
4 AAX56570 USA 11/22/2001 A/New York/71/2001
5 AAX56490 USA 11/27/2001 A/New York/124/2001
6 AAX11625 USA 12/15/2001 A/New York/83/2001
7 AAX35861 USA 12/23/2001 A/New York/131/2001
8 AAY28335 USA 12/25/2001 A/New York/94/2001
9 ACF36396 Hong Kong 12/26/2001 A/Hong Kong/CUHK51424/2001
10 ACF36397 Hong Kong 12/26/2001 A/Hong Kong/CUHK51431/2001
11 ACF36398 Hong Kong 12/28/2001 A/Hong Kong/CUHK51490/2001
12 AAX12761 USA 12/29/2001 A/New York/84/2001
13 AAX56440 USA 12/31/2001 A/New York/85/2001
14 ACC77886 China 1/1/2002 A/Tianjin/5/2002
15 ACC77887 USA 1/1/2002 A/Louisiana/2/2002
16 ACC77888 USA 1/4/2002 A/Oklahoma/2/2002
17 ABA42335 USA 1/4/2002 A/New York/403/2002
18 ACC77889 USA 1/5/2002 A/Utah/6/2002
19 ACC77891 China 1/7/2002 A/Beijing/20/2002
20 ABA42989 USA 1/7/2002 A/New York/405/2002
21 ACC66370 Singapore 1/7/2002 A/SINGAPORE/2/2002
22 ACC66386 Australia 1/9/2002 A/VICTORIA/103/2002
23 ACC66387 Australia 1/9/2002 A/VICTORIA/105/2002
24 ACF36405 Hong Kong 1/10/2002 A/Hong Kong/CUHK5250/2002
25 ACF36406 Hong Kong 1/10/2002 A/Hong Kong/CUHK5251/2002
26 ACC77895 China 1/10/2002 A/Wuhan/12/2002
27 ABA42368 USA 1/11/2002 A/New York/408/2002
28 ACC66544 Australia 1/12/2002 A/VICTORIA/102/2003
29 ACF36411 Hong Kong 1/12/2002 A/Hong Kong/CUHK5296/2002
30 AAX56460 USA 1/12/2002 A/New York/89/2002
31 ABR15962 New Zealand 1/14/2002 A/Auckland/614/2002
32 ABA42379 USA 1/14/2002 A/New York/409/2002
33 AAY47023 USA 1/14/2002 A/New York/125/2002
34 ABA42487 USA 1/16/2002 A/New York/418/2002
35 AAY28648 USA 1/16/2002 A/New York/107/2002
36 ACC77896 China 1/17/2002 A/Wuhan/16/2002
37 ABR14636 Norway 1/17/2002 A/Oslo/398/2002
38 AAX12771 USA 1/17/2002 A/New York/91/2002
39 AAX47525 USA 1/18/2002 A/New York/96/2002
40 ABA42498 USA 1/18/2002 A/New York/419/2002
41 ACC77897 Hong Kong 1/19/2002 A/Hong Kong/1550/2002
42 AAX56580 USA 1/20/2002 A/New York/106/2002
43 AAX12791 USA 1/22/2002 A/New York/100/2002
44 ABA42401 USA 1/22/2002 A/New York/411/2002
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45 ACC77898 USA 1/23/2002 A/New York/16/2002
46 ACC66371 Singapore 1/24/2002 A/SINGAPORE/7/2002
47 AAX56510 USA 1/27/2002 A/New York/132/2002
48 ABB04983 USA 1/28/2002 A/New York/420/2002
49 AAX11635 USA 1/29/2002 A/New York/110/2002
50 AAY44641 USA 1/30/2002 A/New York/118/2002
51 ABG48082 New Zealand 1/31/2002 A/Waikato/2/2002
52 AAX56590 USA 1/31/2002 A/New York/108/2002
53 AAX12801 USA 1/31/2002 A/New York/113/2002
54 ABA42412 USA 2/1/2002 A/New York/412/2002
55 ABI21508 USA 2/1/2002 A/New York/C4/2002
56 ACC77901 USA 2/1/2002 A/Massachusetts/2/2002
57 ACC77902 USA 2/4/2002 A/New York/18/2002
58 AAY28014 USA 2/4/2002 A/New York/101/2002
59 AAX56470 USA 2/6/2002 A/New York/90/2002
60 ABG48093 New Zealand 2/10/2002 A/Wellington/6/2002
61 AAY44620 USA 2/12/2002 A/New York/75/2002
62 AAX47515 USA 2/12/2002 A/New York/129/2002
63 AAX35871 USA 2/14/2002 A/New York/135/2002
64 ACC66327 Australia 2/18/2002 A/BRISBANE/3/2002
65 AAX57784 USA 2/19/2002 A/New York/120/2002
66 ACC77904 USA 2/21/2002 A/North Carolina/6/2002
67 ACC66353 Japan 2/23/2002 A/FUKUOKA/15/2002
68 ACC77905 USA 2/24/2002 A/Illinois/1/2002
69 BAG28225 Japan 2/25/2002 A/Morioka/34/2002
70 AAY28325 USA 2/26/2002 A/New York/88/2002
71 AAX12781 USA 2/26/2002 A/New York/95/2002
72 ABA42476 USA 2/28/2002 A/New York/416/2002
73 AAX35841 USA 3/1/2002 A/New York/86/2002
74 ACF36221 Hong Kong 3/1/2002 A/Hong Kong/CUHK13216/2002
75 BAG28226 Japan 3/1/2002 A/Morioka/52/2002
76 AAZ38539 USA 3/1/2002 A/New York/126/2002
77 ACF36222 Hong Kong 3/3/2002 A/Hong Kong/CUHK13249/2002
78 ACF36223 Hong Kong 3/4/2002 A/Hong Kong/CUHK13278/2002
79 ABS50064 New Zealand 3/4/2002 A/Auckland/615/2002
80 ACC77909 Thailand 3/4/2002 A/Thailand/128400/2002
81 ACC77910 USA 3/5/2002 A/Hawaii/4/2002
82 ACC77911 Hong Kong 3/6/2002 A/Hong Kong/121715/2002
83 AAY98077 USA 3/7/2002 A/New York/276/2002
84 ACC66376 Thailand 3/8/2002 A/SONGKHLA/107/2002
85 AAX57734 USA 3/11/2002 A/New York/130/2002
86 AAY28405 USA 3/21/2002 A/New York/122/2002
87 ACC77912 Hong Kong 3/25/2002 A/Hong Kong/568/2002
88 ACC66323 Thailand 3/25/2002 A/BANGKOK/109/2002
89 ACC77913 USA 4/3/2002 A/Washington/3/2002
90 ACC77914 Brazil 4/4/2002 A/Ceara/177/2002
91 ACF36278 Hong Kong 4/4/2002 A/Hong Kong/CUHK21713/2002
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92 ACC66361 New Caledonia 4/4/2002 A/New Caledonia/6/2002
93 ACF36281 Hong Kong 4/8/2002 A/Hong Kong/CUHK21742/2002
94 ACF36284 Hong Kong 4/11/2002 A/Hong Kong/CUHK21957/2002
95 ABG37417 New Zealand 4/12/2002 A/Waikato/5/2002
96 ACC77915 USA 4/17/2002 A/Nebraska/12/2002
97 ABC42871 New Zealand 4/26/2002 A/Canterbury/01/2002
98 ABC67850 New Zealand 5/2/2002 A/Canterbury/14/2002
99 ACF36299 Hong Kong 5/10/2002 A/Hong Kong/CUHK23113/2002
100 ACF36300 Hong Kong 5/10/2002 A/Hong Kong/CUHK23162/2002
101 ACF36301 Hong Kong 5/12/2002 A/Hong Kong/CUHK23180/2002
102 ACC77916 Argentina 5/14/2002 A/Argentina/1/2002
103 ACC77917 Peru 5/14/2002 A/Peru/3029/2002
104 ACC77918 China 5/14/2002 A/Guangzhou/394/2002
105 ACC66394 Australia 5/20/2002 A/VICTORIA/506/2002
106 ACC77919 Brazil 5/23/2002 A/Brazil/1727/2002
107 ACF36302 Hong Kong 6/1/2002 A/Hong Kong/CUHK24044/2002
108 ACF36303 Hong Kong 6/2/2002 A/Hong Kong/CUHK24054/2002
109 ACF36304 Hong Kong 6/3/2002 A/Hong Kong/CUHK24114/2002
110 ACF36305 Hong Kong 6/4/2002 A/Hong Kong/CUHK24167/2002
111 ACC77920 Hong Kong 6/6/2002 A/Hong Kong/1143/2002
112 ABI92335 New Zealand 6/7/2002 A/Dunedin/1/2002
113 ACC66328 Australia 6/7/2002 A/BRISBANE/5/2002
114 ABC50255 New Zealand 6/8/2002 A/Canterbury/47/2002
115 ABR28856 New Zealand 6/8/2002 A/Auckland/608/2002
116 ABC50299 New Zealand 6/10/2002 A/Canterbury/53/2002
117 ABC50288 New Zealand 6/11/2002 A/Canterbury/50/2002
118 ACC66347 New Zealand 6/13/2002 A/CHRISTCHURCH/37/2002
119 ABC68049 New Zealand 6/13/2002 A/South Canterbury/37/2002
120 ABG37428 New Zealand 6/17/2002 A/Wellington/38/2002
121 ABC67989 New Zealand 6/20/2002 A/Canterbury/33/2002
122 ACC66329 Australia 6/20/2002 A/BRISBANE/6/2002
123 ABG88806 Australia 6/25/2002 A/Western Australia/23/2002
124 ABC67653 New Zealand 6/27/2002 A/Canterbury/57/2002
125 ACC77922 Brazil 6/27/2002 A/Brazil/1732/2002
126 ABC85952 New Zealand 6/30/2002 A/Canterbury/60/2002
127 ABG37450 New Zealand 7/1/2002 A/Waikato/21/2002
128 ACC66324 Thailand 7/1/2002 A/BANGKOK/190/2002
129 ACF36339 Hong Kong 7/1/2002 A/Hong Kong/CUHK33047/2002
130 ABC50321 New Zealand 7/2/2002 A/Canterbury/59/2002
131 ACF36340 Hong Kong 7/2/2002 A/Hong Kong/CUHK33079/2002
132 ACF36341 Hong Kong 7/2/2002 A/Hong Kong/CUHK33106/2002
133 ACC66373 Singapore 7/2/2002 A/SINGAPORE/29/2002
134 ABI92346 New Zealand 7/3/2002 A/Waikato/23/2002
135 ACC66381 Australia 7/4/2002 A/SYDNEY/23/2002
136 ABC68093 New Zealand 7/6/2002 A/Canterbury/72/2002
137 ABC85919 New Zealand 7/6/2002 A/Canterbury/70/2002
138 ACC66380 Australia 7/7/2002 A/SYDNEY/21/2002
13
139 ABG26956 New Zealand 7/9/2002 A/Dunedin/10/2002
140 ACC66321 New Zealand 7/9/2002 A/AUCKLAND/26/2002
141 ABC67543 New Zealand 7/9/2002 A/Canterbury/79/2002
142 ABC50376 New Zealand 7/9/2002 A/Canterbury/81/2002
143 ABI92555 Australia 7/10/2002 A/Western Australia/25/2002
144 ABC50354 New Zealand 7/11/2002 A/Canterbury/75/2002
145 ABC50365 New Zealand 7/11/2002 A/Canterbury/80/2002
146 ABG48137 New Zealand 7/15/2002 A/Wellington/71/2002
147 ACC66330 Australia 7/15/2002 A/BRISBANE/22/2002
148 ACC66331 Australia 7/17/2002 A/BRISBANE/45/2002
149 ACC77923 Philippines 7/17/2002 A/Philippines/160283/2002
150 ACC66367 Philippines 7/18/2002 A/PHILIPPINES/471/2002
151 ABK39951 Australia 7/21/2002 A/Western Australia/27/2002
152 ABG88630 New Zealand 7/23/2002 A/Waikato/36/2002
153 ACC77926 Hong Kong 7/26/2002 A/Hong Kong/1510/2002
154 ABI92577 Australia 8/6/2002 A/Western Australia/28/2002
155 ACC66335 Australia 8/8/2002 A/BRISBANE/144/2002
156 ACC77928 Brazil 8/9/2002 A/Brazil/2458/2002
157 ABH01014 China 8/11/2002 A/Fujian/411/2002
158 ACC66336 Australia 8/11/2002 A/BRISBANE/157/2002
159 ACC66352 China 8/11/2002 A/Fujian/411/2002
160 ABP51971 China 8/11/2002 A/Fujian/411/2002
161 ABG88641 New Zealand 8/12/2002 A/Dunedin/18/2002
162 ABK80179 Australia 8/13/2002 A/Queensland/23/2002
163 ABL67308 Australia 8/13/2002 A/Queensland/27/2002
164 ACC66338 Australia 8/13/2002 A/BRISBANE/192/2002
165 ACC77929 India 8/16/2002 A/India/25502/2002
166 ABI92599 Australia 8/19/2002 A/Western Australia/30/2002
167 ABG48170 New Zealand 8/20/2002 A/Wellington/79/2002
168 ACC66364 Australia 8/21/2002 A/PERTH/49/2002
169 ACC66391 Australia 8/22/2002 A/VICTORIA/235/2002
170 ABG37472 New Zealand 8/23/2002 A/Waikato/58/2002
171 ABN51154 Australia 8/28/2002 A/Western Australia/34/2002
172 ACC66322 New Zealand 9/3/2002 A/AUCKLAND/57/2002
173 ACC66342 Australia 9/4/2002 A/BRISBANE/312/2002
174 ABR15940 New Zealand 9/9/2002 A/Auckland/611/2002
175 ACC66360 Malaysia 9/9/2002 A/MALAYSIA/145/2002
176 ACC66379 Australia 9/15/2002 A/South Australia/154/2002
177 ACC66392 Australia 9/16/2002 A/VICTORIA/254/2002
178 ACC66383 Taiwan 9/25/2002 A/TAIWAN/8/2002
179 ABI92621 Australia 9/29/2002 A/Western Australia/35/2002
180 ACC66365 Australia 9/29/2002 A/PERTH/89/2002
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Table 6. The sequences of H3N2 viruses after 10/01/2008. Data are from GISAID. The first column
label is the same as used in Figure 5.
Label EPI ID Country Collection date Virus name
(mm/dd/yyyy)
1 1 EPI187670 Japan 4/2/2009 A/AICHI/158/2009
2 EPI187671 Japan 4/9/2009 A/AICHI/161/2009
3 EPI169724 Japan 11/26/2008 A/AKITA/12/2008
4 EPI187672 Japan 5/27/2009 A/AKITA/34/2009
5 EPI185826 USA 2/27/2009 A/Arizona/08/2009
6 EPI185829 USA 2/25/2009 A/Arizona/11/2009
7 EPI185805 Russia 3/23/2009 A/Astrakhan/7/2009
8 EPI185723 China 2/10/2009 A/Beijng-Xicheng/1108/2009
9 EPI189216 Australia 4/28/2009 A/Brisbane/53/2009
10 EPI185704 Canada 3/15/2009 A/British Columbia/RV1222/2009
11 EPI185707 Canada 3/15/2009 A/British Columbia/RV1223/2009
12 EPI187312 Japan 5/1/2009 A/CHIBA-C/42/2009
13 EPI187313 Japan 1/16/2009 A/CHIBA-C/7/2009
14 EPI175111 USA 12/20/2008 A/California/10/2008
15 EPI185831 USA 1/1/2009 A/Colorado/01/2009
16 EPI169244 USA 10/15/2008 A/Colorado/03/2008
17 EPI172436 USA 10/29/2008 A/Colorado/04/2008
18 EPI185834 USA 1/16/2009 A/Colorado/05/2009
19 EPI185837 USA 1/21/2009 A/Colorado/06/2009
20 EPI175119 USA 12/17/2008 A/Colorado/12/2008
21 EPI175120 USA 12/24/2008 A/Colorado/15/2008
22 EPI187314 Japan 12/15/2008 A/EHIME/36/2008
23 EPI187315 Japan 1/19/2009 A/EHIME/9/2009
24 EPI187317 Japan 12/26/2008 A/FUKUOKA-C/39/2008
25 EPI187319 Japan 12/26/2008 A/FUKUSHIMA/124/2008
26 EPI185726 China 11/26/2008 A/Fujian-Siming/1242/2008
27 EPI185729 China 3/3/2009 A/Fujian-Tongan/142/2009
28 EPI187320 Japan 1/28/2009 A/GIFU-C/37/2009
29 EPI187321 Japan 1/28/2009 A/GIFU-C/38/2009
30 EPI172442 Guam 10/27/2008 A/Guam/7124/2008
31 EPI187322 Japan 2/3/2009 A/HIROSHIMA-C/20/2009
32 EPI187323 Japan 1/6/2009 A/HIROSHIMA-C/7/2009
33 EPI187674 Japan 5/26/2009 A/HIROSHIMA/148/2009
34 EPI187675 Japan 6/10/2009 A/HIROSHIMA/154/2009
35 EPI187324 Japan 12/6/2008 A/HOKKAIDO/9/2008
36 EPI187325 Japan 11/29/2008 A/HYOGO/6/2008
37 EPI187326 Japan 12/11/2008 A/HYOGO/99/2008
38 EPI185840 USA 1/6/2009 A/Hawaii/02/2009
39 EPI185842 USA 1/30/2009 A/Hawaii/05/2009
40 EPI185845 USA 3/28/2009 A/Hawaii/06/2009
41 EPI185851 USA 3/30/2009 A/Hawaii/07/2009
42 EPI185848 USA 3/30/2009 A/Hawaii/07/2009
43 EPI185854 USA 2/11/2009 A/Hawaii/10/2009
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44 EPI185857 USA 4/15/2009 A/Hawaii/14/2009
45 EPI185860 USA 4/19/2009 A/Hawaii/15/2009
46 EPI185863 USA 4/20/2009 A/Hawaii/16/2009
47 EPI172430 USA 11/10/2008 A/Hawaii/47/2008
48 EPI185732 China 2/1/2009 A/Heilongjiang-Nangang/134/2009
49 EPI185735 China 2/10/2009 A/Heilongjiang-Xiangfang/163/2009
50 EPI185779 Honduras 5/5/2009 A/Honduras/56/2009
51 EPI185782 Honduras 5/6/2009 A/Honduras/639/2009
52 EPI185738 China 2009/00/00 A/Hong Kong/03/2009
53 EPI185741 China 4/7/2009 A/Hong Kong/1999/2009
54 EPI185744 China 4/7/2009 A/Hong Kong/2000/2009
55 EPI185747 China 4/6/2009 A/Hong Kong/2007/2009
56 EPI185750 China 4/5/2009 A/Hong Kong/2008/2009
57 EPI175154 China 10/8/2008 A/Hong Kong/3134/2008
58 EPI185754 China 1/6/2009 A/Hong Kong/40/2009
59 EPI187329 Japan 1/6/2009 A/IWATE/4/2009
60 EPI185866 USA 3/14/2009 A/Idaho/04/2009
61 EPI172414 USA 10/7/2008 A/Idaho/17/2008
62 EPI171404 USA 10/16/2008 A/Idaho/18/2008
63 EPI185868 USA 1/19/2009 A/Indiana/02/2009
64 EPI185871 USA 4/15/2009 A/Indiana/10/2009
65 EPI185873 USA 1/2/2009 A/Iowa/03/2009
66 EPI173166 Kenya 10/8/2008 A/Isiolo/7514/2008
67 EPI185785 Jamaica 4/28/2009 A/Jamaica/2970/2009
68 EPI185757 China 3/12/2009 A/Jiangsu-Quanshan/114/2009
69 EPI187676 China 2/13/2009 A/Jiangsu-quanshan/38/2009
70 EPI187330 China 2/24/2009 A/Jiangxi-xihu/37/2009
71 EPI169726 Japan 11/12/2008 A/KANAGAWA/61/2008
72 EPI169727 Japan 11/12/2008 A/KANAGAWA/65/2008
73 EPI187331 Japan 1/26/2009 A/KOBE/33/2009
74 EPI187332 Japan 12/17/2008 A/KOBE/61/2008
75 EPI187333 Japan 4/5/2009 A/KOBE/84/2009
76 EPI187334 Japan 1/23/2009 A/KOCHI/35/2009
77 EPI187335 Japan 12/6/2008 A/KOCHI/53/2008
78 EPI187337 Japan 1/23/2009 A/KYOTO/12/2009
79 EPI187338 Japan 11/25/2008 A/KYOTO/19/2008
80 EPI187339 Japan 11/19/2008 A/KYOTO/20/2008
81 EPI187677 Japan 5/22/2009 A/KYOTO/30/2009
82 EPI187340 Japan 1/16/2009 A/KYOTO/8/2009
83 EPI185875 USA 2009/00/00 A/Kentucky/02/2009
84 EPI185789 Kenya 10/3/2008 A/Kenya/2234/2008
85 EPI185791 Kenya 10/15/2008 A/Kenya/2282/2008
86 EPI185793 Kenya 10/21/2008 A/Kenya/2297/2008
87 EPI173167 Kenya 11/7/2008 A/Kericho/7532/2008
88 EPI173168 Kenya 11/10/2008 A/Kericho/7533/2008
89 EPI173169 Kenya 11/10/2008 A/Kericho/7534/2008
90 EPI173173 Kenya 10/6/2008 A/Kisii/7544/2008
16
91 EPI173174 Kenya 10/8/2008 A/Kisii/7546/2008
92 EPI173175 Kenya 10/14/2008 A/Kisii/7548/2008
93 EPI173176 Kenya 10/15/2008 A/Kisii/7549/2008
94 EPI173177 Kenya 10/16/2008 A/Kisii/7551/2008
95 EPI173178 Kenya 10/17/2008 A/Kisii/7552/2008
96 EPI173179 Kenya 10/17/2008 A/Kisii/7553/2008
97 EPI173180 Kenya 10/17/2008 A/Kisii/7555/2008
98 EPI173181 Kenya 10/21/2008 A/Kisii/7556/2008
99 EPI173182 Kenya 10/23/2008 A/Kisii/7558/2008
100 EPI173183 Kenya 10/28/2008 A/Kisii/7563/2008
101 EPI173184 Kenya 11/4/2008 A/Kisii/7566/2008
102 EPI173185 Kenya 11/5/2008 A/Kisii/7568/2008
103 EPI173186 Kenya 11/5/2008 A/Kisii/7569/2008
104 EPI173193 Kenya 10/3/2008 A/Kisumu/7599/2008
105 EPI173194 Kenya 10/6/2008 A/Kisumu/7600/2008
106 EPI173195 Kenya 10/6/2008 A/Kisumu/7601/2008
107 EPI173196 Kenya 10/6/2008 A/Kisumu/7602/2008
108 EPI173197 Kenya 10/7/2008 A/Kisumu/7603/2008
109 EPI173198 Kenya 10/7/2008 A/Kisumu/7604/2008
110 EPI173199 Kenya 10/8/2008 A/Kisumu/7605/2008
111 EPI173200 Kenya 10/21/2008 A/Kisumu/7609/2008
112 EPI173201 Kenya 10/24/2008 A/Kisumu/7612/2008
113 EPI173202 Kenya 10/28/2008 A/Kisumu/7613/2008
114 EPI173203 Kenya 10/29/2008 A/Kisumu/7614/2008
115 EPI173204 Kenya 11/4/2008 A/Kisumu/7618/2008
116 EPI173205 Kenya 11/4/2008 A/Kisumu/7621/2008
117 EPI173164 Kenya 11/10/2008 A/Kisumu/7627/2008
118 EPI185811 South Korea 12/8/2008 A/Korea/7719/2008
119 EPI185813 South Korea 12/9/2008 A/Korea/7723/2008
120 EPI185815 South Korea 12/13/2008 A/Korea/7858/2008
121 EPI185818 South Korea 12/13/2008 A/Korea/7858/2008
122 EPI185797 Kuwait 1/18/2009 A/Kuwait/494/2009
123 EPI185760 China 12/4/2008 A/Liaoning-Tiedong/14/2008
124 EPI169728 Japan 12/3/2008 A/MIE/34/2008
125 EPI169729 Japan 12/3/2008 A/MIE/36/2008
126 EPI187341 Japan 12/22/2008 A/MIE/43/2008
127 EPI187343 Japan 12/3/2008 A/MIYAGI/36/2008
128 EPI186304 Malaysia 1/6/2009 A/Malaysia/0032/2009
129 EPI173187 Kenya 10/2/2008 A/Malindi/7579/2008
130 EPI173188 Kenya 10/9/2008 A/Malindi/7581/2008
131 EPI173189 Kenya 11/11/2008 A/Malindi/7590/2008
132 EPI185877 USA 1/20/2009 A/Maryland/02/2009
133 EPI175206 USA 12/5/2008 A/Maryland/10/2008
134 EPI185879 USA 1/20/2009 A/Massachusetts/01/2009
135 EPI185881 USA 1/9/2009 A/Massachusetts/02/2009
136 EPI171405 USA 10/29/2008 A/Massachusetts/06/2008
137 EPI172416 USA 10/29/2008 A/Massachusetts/06/2008
17
138 EPI175211 USA 12/12/2008 A/Massachusetts/13/2008
139 EPI173190 Kenya 11/12/2008 A/Mbagathi/7593/2008
140 EPI185800 Mexico 3/11/2009 A/Mexico/2779/2009
141 EPI175226 USA 12/28/2008 A/Minnesota/36/2008
142 EPI185883 USA 12/23/2008 A/Minnesota/37/2008
143 EPI172444 USA 12/9/2008 A/Montana/02/2008
144 EPI185886 USA 3/3/2009 A/Montana/04/2009
145 EPI185889 USA 1/26/2009 A/Montana/05/2009
146 EPI169730 Japan 11/20/2008 A/NAGANO/1201/2008
147 EPI187353 Japan 12/18/2008 A/NAGOYA/10/2008
148 EPI187357 Japan 2009/00/00 A/NAGOYA/6/2009
149 EPI187359 Japan 3/12/2009 A/NIIGATA/403/2009
150 EPI187679 Japan 5/19/2009 A/NIIGATA/603/2009
151 EPI187680 Japan 6/1/2009 A/NIIGATA/662/2009
152 EPI185891 USA 12/22/2008 A/Nebraska/08/2008
153 EPI185894 USA 4/8/2009 A/Nevada/06/2009
154 EPI185896 USA 2/16/2009 A/New Hampshire/01/2009
155 EPI185899 USA 2/28/2009 A/New Hampshire/04/2009
156 EPI185900 USA 1/27/2009 A/New Mexico/03/2009
157 EPI185904 USA 2/22/2009 A/New York/67/2009
158 EPI185906 USA 12/29/2008 A/North Carolina/08/2008
159 EPI175252 USA 12/15/2008 A/North Dakota/02/2008
160 EPI187682 Japan 5/20/2009 A/OKINAWA/25/2009
161 EPI187684 Japan 5/22/2009 A/OKINAWA/38/2009
162 EPI185908 USA 2/24/2009 A/Oregon/03/2009
163 EPI185910 USA 1/22/2009 A/Pennsylvania/02/2009
164 EPI185913 USA 3/8/2009 A/Pennsylvania/05/2009
165 EPI175262 USA 12/11/2008 A/Pennsylvania/13/2008
166 EPI187703 Australia 4/7/2009 A/Perth/15/2009
167 EPI187702 Australia 4/7/2009 A/Perth/15/2009
168 EPI185159 Australia 4/7/2009 A/Perth/15/2009
169 EPI182941 Australia 4/7/2009 A/Perth/16/2009
170 EPI185157 Australia 4/7/2009 A/Perth/16/2009
171 EPI182939 Philippines 3/5/2009 A/Philippines/16/2009
172 EPI173240 Philippines 11/26/2008 A/Philippines/3803/2008
173 EPI182937 Philippines 3/5/2009 A/Philippines/5/2009
174 EPI185802 Puerto Rico 2/9/2009 A/Puerto Rico/18/2009
175 EPI185709 Canada 1/23/2009 A/Quebec/RV0623/2009
176 EPI185712 Canada 2/11/2009 A/Quebec/RV0899/2009
177 EPI185715 Canada 3/3/2009 A/Quebec/RV1069/2009
178 EPI185718 Canada 3/3/2009 A/Quebec/RV1069/2009
179 EPI187360 Japan 12/19/2008 A/SAGA/204/2008
180 EPI187364 Japan 12/19/2008 A/SAITAMA/47/2008
181 EPI169732 Japan 11/9/2008 A/SAKAI/33/2008
182 EPI187685 Japan 4/28/2009 A/SAKAI/41/2009
183 EPI187366 Japan 12/6/2008 A/SAKAI/53/2008
184 EPI187686 Japan 5/13/2009 A/SAPPORO/112/2009
18
185 EPI172133 Japan 12/9/2008 A/SHIMANE/106/2008
186 EPI172134 Japan 12/8/2008 A/SHIMANE/107/2008
187 EPI172135 Japan 12/18/2008 A/SHIZUOKA-C/55/2008
188 EPI187374 Japan 12/26/2008 A/SHIZUOKA-C/57/2008
189 EPI187377 Japan 2/20/2009 A/SHIZUOKA/428/2009
190 EPI187378 Japan 2/23/2009 A/SHIZUOKA/448/2009
191 EPI187379 Japan 2/26/2009 A/SHIZUOKA/502/2009
192 EPI187687 Japan 5/23/2009 A/SHIZUOKA/736/2009
193 EPI187688 Japan 6/14/2009 A/SHIZUOKA/791/2009
194 EPI185720 Canada 1/5/2009 A/Saskatchewan/RV0101/2009
195 EPI185763 China 2/22/2009 A/Shanghai-Nanhui/146/2009
196 EPI185766 China 3/12/2009 A/Shanghai-Nanhui/190/2009
197 EPI185769 China 11/4/2008 A/Sichuan-Qingyang/1396/2008
198 EPI175268 China 11/4/2008 A/Sichuan/Qingyang1396/2008
199 EPI190150 Singapore 6/1/2009 A/Singapore/33/2009
200 EPI182943 Singapore 3/27/2009 A/Singapore/39/2009
201 EPI173242 Singapore 11/25/2008 A/Singapore/619/2008
202 EPI185915 USA 12/31/2008 A/South Carolina/07/2008
203 EPI185808 Russia 3/30/2009 A/St. Petersburg/92/2009
204 EPI186310 Australia 1/12/2009 A/Sydney/1/2009
205 EPI186311 Australia 1/20/2009 A/Sydney/3/2009
206 EPI187699 Japan 5/18/2009 A/TOCHIGI/140/2009
207 EPI169744 Japan 11/4/2008 A/TOKUSHIMA/18/2008
208 EPI187394 Japan 12/18/2008 A/TOTTORI/82/2008
209 EPI187694 Taiwan 2/13/2009 A/Taiwan/240/2009
210 EPI169737 Taiwan 10/3/2008 A/Taiwan/540/2008
211 EPI169738 Taiwan 10/3/2008 A/Taiwan/542/2008
212 EPI169739 Taiwan 10/12/2008 A/Taiwan/548/2008
213 EPI169740 Taiwan 10/18/2008 A/Taiwan/549/2008
214 EPI169741 Taiwan 10/31/2008 A/Taiwan/573/2008
215 EPI169742 Taiwan 11/7/2008 A/Taiwan/580/2008
216 EPI169743 Taiwan 11/13/2008 A/Taiwan/599/2008
217 EPI172448 Taiwan 10/25/2008 A/Taiwan/611/2008
218 EPI172450 Taiwan 11/8/2008 A/Taiwan/612/2008
219 EPI187696 Taiwan 5/2/2009 A/Taiwan/712/2009
220 EPI187697 Taiwan 5/2/2009 A/Taiwan/714/2009
221 EPI187698 Taiwan 4/23/2009 A/Taiwan/725/2009
222 EPI185918 USA 1/26/2009 A/Texas/02/2009
223 EPI185920 USA 3/4/2009 A/Texas/03/2009
224 EPI185923 USA 3/18/2009 A/Texas/18/2009
225 EPI175295 USA 12/26/2008 A/Texas/39/2008
226 EPI185820 Thailand 10/3/2008 A/Thailand/860/2008
227 EPI175300 Thailand 11/6/2008 A/Thailand/944/2008
228 EPI175302 Thailand 11/3/2008 A/Thailand/947/2008
229 EPI185823 Thailand 11/12/2008 A/Thailand/981/2008
230 EPI175305 Thailand 11/3/2008 A/Thailand/998/2008
231 EPI185772 China 3/3/2009 A/Tianjin-Hongqiao/141/2009
19
232 EPI185774 China 12/30/2008 A/Tianjin-Nankai/1211/2008
233 EPI185949 Trinidad and Tobago 2009/00/00 A/Trinidad/2940/2009
234 EPI185925 USA 2/13/2009 A/Vermont/02/2009
235 EPI189220 Australia 6/2/2009 A/Victoria/208/2009
236 EPI189218 Australia 6/2/2009 A/Victoria/209/2009
237 EPI190148 Australia 6/2/2009 A/Victoria/210/2009
238 EPI173254 Australia 1/12/2009 A/Victoria/500/2009
239 EPI176481 Australia 1/25/2009 A/Victoria/502/2009
240 EPI185927 USA 1/5/2009 A/Virginia/02/2009
241 EPI187395 Japan 1/13/2009 A/WAKAYAMA/14/2009
242 EPI185929 USA 1/25/2009 A/Washington/04/2009
243 EPI185931 USA 3/3/2009 A/Washington/05/2009
244 EPI185934 USA 3/30/2009 A/Washington/06/2009
245 EPI172418 USA 12/8/2008 A/Washington/09/2008
246 EPI185937 USA 4/6/2009 A/Washington/15/2009
247 EPI185940 USA 3/16/2009 A/Washington/16/2009
248 EPI185942 USA 1/7/2009 A/Wisconsin/03/2009
249 EPI185944 USA 2/5/2009 A/Wisconsin/05/2009
250 EPI172434 USA 12/3/2008 A/Wisconsin/18/2008
251 EPI175344 USA 12/25/2008 A/Wisconsin/23/2008
252 EPI175346 USA 12/23/2008 A/Wisconsin/24/2008
253 EPI185946 USA 2/2/2009 A/Wyoming/02/2009
254 EPI187396 Japan 11/15/2008 A/YAMAGATA/111/2008
255 EPI187397 Japan 11/16/2008 A/YAMAGATA/112/2008
256 EPI187398 Japan 1/13/2009 A/YAMAGUCHI/15/2009
257 EPI172138 Japan 12/3/2008 A/YAMAGUCHI/30/2008
258 EPI172139 Japan 12/8/2008 A/YAMAGUCHI/35/2008
259 EPI187400 Japan 11/5/2008 A/YAMANASHI/140/2008
260 EPI187402 Japan 3/8/2009 A/YOKOHAMA/107/2009
261 EPI187403 Japan 3/4/2009 A/YOKOHAMA/108/2009
262 EPI187404 Japan 1/27/2009 A/YOKOHAMA/52/2009
263 EPI172142 Japan 12/2/2008 A/YOKOHAMA/97/2008
